Assyro AI

Orange Book product · Brand (NDA)

NINLARO

IXAZOMIB CITRATE

Brand (NDA)NDA 208462RX TAKEDA PHARMS USA

At a glance

Nov 20, 2015

Approved

Brand (NDA)

Application

Not listed

TE code

7

Listed patents

Key dates

  1. Approval

    FDA approval date of this drug product.

    Nov 20, 2015

    10 yr 9 mo ago

  2. Today

  3. Patent 7687662 expires

    Listed drug substance patent expiration.

    Aug 06, 2027

    in 1 yr 2 mo

  4. Patent 8003819 expires

    Listed drug substance patent expiration.

    Aug 06, 2027

    in 1 yr 2 mo

  5. Patent 8530694 expires

    Listed drug substance patent expiration.

    Aug 06, 2027

    in 1 yr 2 mo

  6. Patent 8871745 expires

    Listed method-of-use patent (U-2434) expiration.

    Aug 06, 2027

    in 1 yr 2 mo

  7. Patent 8859504 expires

    Listed drug substance patent expiration.

    Jun 16, 2029

    in 3 yr

  8. Patent 9175017 expires

    Listed method-of-use patent (U-2434) expiration.

    Jun 16, 2029

    in 3 yr

  9. Patent 7442830 expires

    Listed drug substance patent expiration.

    Nov 20, 2029

    in 3 yr 6 mo

Pharmaceutical detail

Active ingredient

IXAZOMIB CITRATE

Strength

EQ 4MG BASE

Dosage form

CAPSULE

Route

ORAL

TE code

Not listed

Application

NDA 208462

Product number

003

Marketing status

RX

Reference listed drug (RLD)

Yes

Reference standard (RS)

Yes

Active-ingredient family

View full family

This is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.

Listed patents (7)

Patents listed in the FDA Orange Book for this product, with expiration date and patent type.
PatentExpiresInType
7687662Aug 06, 2027in 1 yr 2 mo
SubstanceProduct
8003819Aug 06, 2027in 1 yr 2 mo
SubstanceProductU-2434
8530694Aug 06, 2027in 1 yr 2 mo
SubstanceProductU-2434
8871745Aug 06, 2027in 1 yr 2 mo
U-2434
8859504Jun 16, 2029in 3 yr
SubstanceProduct
9175017Jun 16, 2029in 3 yr
U-2434
7442830Nov 20, 2029in 3 yr 6 mo
SubstanceProductU-2434
Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.